Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
Takeda exercised its option to acquire GammaDelta for a pre-negotiated upfront payment as well as potential development and regulatory milestones.
- Takeda exercised its option to acquire GammaDelta for a pre-negotiated upfront payment as well as potential development and regulatory milestones.
- The acquisition follows a multi-year collaboration between Takeda and GammaDelta Therapeutics formed in 2017 to develop GammaDeltas novel T cell therapy platforms, in which Takeda received an equity stake and an exclusive right to purchase GammaDelta.
- GammaDelta Therapeutics (GammaDelta) is clinically-staged biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer.
- GammaDelta is advancing its novel, T cell platforms and product candidates under an ongoing collaboration with Takeda Pharmaceutical Company Limited (Takeda).